AuthorisedTherapeutic exploratory (Phase II)Interventional

DIMREATOX study - Reduction in digestive absorption of toxic substances by combined digestive decontamination in intensive care - randomized single-center study

This study, called DIMREATOX, is testing new ways to help critically ill patients in intensive care who have been poisoned by toxic substances. These patients are so unwell they need a breathing machine. The study aims to see if a combination of certain medications, given as a drink, can help their bodies get rid of these harmful substances more quickly. Researchers will measure how much of the toxic substance is in the patient's blood over time to see if the treatment is working. We also want to understand if this approach can help patients recover faster, spend less time on breathing machines, and have fewer complications. It's an early-stage study to understand if this treatment could be helpful in the future.

At a glance

Status

Authorised

Phase

Therapeutic exploratory (Phase II)

Sponsor

Assistance Publique Hopitaux De Paris

Enrolment target

200

Start

21 Jul 2025

Major patients intoxicated by functional toxicant(s)hospitalized in intensive care and intubated.

What is this study about?

When someone accidentally takes a dangerous substance, it can make them very sick, sometimes needing care in an intensive care unit (ICU) and a breathing machine. The DIMREATOX study is looking for better ways to help these patients. The main idea is to use a special combination of drinks (medicines called FORTRANS and TOXICARB) that might help reduce how much of the harmful substance their body absorbs from their gut. This could speed up the removal of the toxins and hopefully help patients recover more quickly.

Researchers will carefully measure the levels of the toxic substance in the patient's blood over several days to see if the treatments are effectively clearing it from the body. They will compare these levels to see how much they change after the treatment starts. This will tell them if the medicines are doing their job.

Beyond just clearing the toxins, the study also wants to see if this approach improves other important aspects of a patient's recovery. This includes how long they need to be on a breathing machine, how long they need intensive care support, and if they experience fewer side effects like sickness or tummy problems. It's an important step to find new and more effective ways to treat severe poisoning.

Key takeaways

This study is for adults poisoned by dangerous substances.
It tests new medicines to help remove toxins from the body.
Patients must be in intensive care and on a breathing machine.
The study aims to improve recovery for very sick patients.
It's an early-stage study to see if these treatments are effective.

Who may be eligible?

To be considered for this study, patients must be adults, aged 18 or older. They can be male or female.

Crucially, they must be in intensive care because they have taken a dangerous substance. They also need to be on a breathing machine (intubated) because they are so unwell.

The medical team will carefully check all health details to make sure the study is a good fit and safe for each patient. They will explain everything to the patient or their family.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Are you or your loved one in intensive care due to poisoning?
Do you or your loved one need a breathing machine?
Has a doctor confirmed that the poisoning is from a 'functional toxicant'?

Answer every question to see your result.

What does participation involve?

If a patient is eligible for this study, they will receive a special combination of medicines as a drink. Researchers will regularly take blood samples to measure the levels of the toxic substance in their body over 24, 48, 72, and 96 hours (4 days). The medical team will also keep a close eye on other aspects of their health, such as how long they need breathing support, if they vomit, or if they develop tummy pain. The study will last for 28 days after starting the treatment, during which their overall recovery will be monitored. Standard intensive care treatments will continue as needed throughout this time.

Potential risks and benefits

This study is exploring a new way to help critically ill patients, and while there's no guarantee of direct benefit for every participant, the potential benefit is helping their body remove harmful substances faster and potentially improving their recovery. As with all medications, there's always a possibility of side effects, such as tummy problems (like pain or diarrhoea) or, rarely, a severe allergic reaction. The medical team will monitor participants very closely for any of these issues. Patients or their legal representatives always have the right to withdraw from the study at any time without affecting their medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
France

Common questions

What does 'toxic substance' mean?

It means any harmful chemical or drug that someone has accidentally taken into their body, causing them to become very sick.

Why is this study important?

It's important because it's looking for new and better ways to help people who are very ill due to poisoning, aiming to speed up their recovery and reduce complications.

What are FORTRANS and TOXICARB?

These are the names of the specific medicines being tested in this study. They are given as drinks to help clear harmful substances from the gut.

What does 'intubated' mean?

It means the patient has a tube placed in their throat to help them breathe, usually connected to a breathing machine. This happens when someone is severely unwell.

How long will the study last for each person?

Participants will be monitored for about 28 days after they start the study medication to see how their recovery progresses.